BioStock: Dicot doses first phase I participants

Dicot recently dosed the first participants in its phase I study with LIB-01. The main objective of the study, which takes place at Uppsala University Hospital, is to evaluate the safety profile of the drug candidate in humans. This marks an important milestone for the company, which has so far had a successful development during 2023.

Read the full article at biostock.se:

https://www.biostock.se/en/2023/09/dicot-doses-first-phase-i-participants/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se